Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Arvinas Inc.
Eli Lilly and Company
Sensei Biotherapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Alume Biosciences, Inc.
Xynomic Pharmaceuticals, Inc.
Salubris Biotherapeutics Inc
NantCell, Inc.
Turning Point Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Genmab
Kineta Inc.
DualityBio Inc.
Genexine, Inc.
Lumos Pharma